EA Pharma to co-promote Humira in Japan with AbbVie GK
Eisai Co. Ltd.'s subsidiary EA Pharma Co. Ltd. received rights to co-promote in Japan AbbVie Inc.'s (through its Japanese subsidiary AbbVie GK) fully human anti-TNF-a monoclonal antibody Humira (adalimumab) for gastrointestinal disease indications including ulcerative colitis, Crohn’s disease, and intestinal Behçet’s disease.
- Large Molecule
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.